phase 2: Vargatef (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer - Full Text View - ClinicalTrials.gov - France) (treatment/placebo/note: Avastin...)

Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer - Full Text View - ClinicalTrials.gov

This study is not yet open for participant recruitment.

Verified April 2012 by ARCAGY/ GINECO GROUP

First Received on April 19, 2012.   Last Updated on April 23, 2012   History of Changes

Sponsor:	ARCAGY/ GINECO GROUP
Information provided by (Responsible Party):	ARCAGY/ GINECO GROUP
ClinicalTrials.gov Identifier:	NCT01583322

  Purpose

Patients with extensive and bulky disease are often those whose initial surgery is delayed after 3 or 4 cycles of neo-adjuvant chemotherapy.

In that case, there is, indeed, some concern to administer bevacizumab during the chemotherapy surrounding the interval debulking surgery due to the long half life (14- 21 days) of this monoclonal antibody and the interference of anti angiogenic agents with wound healing.

Vargatef® (Nintedanib) might offer a better alternative to bevacizumab in the neo-adjuvant setting. Vargatef® (Nintedanib) has a much shorter half-life of 7 to 19 hours. Preliminary experience in cancer did not show a trend for increased incidence of fistula or bowel perforation. For more details please refer to the investigator drug brochure for Vargatef® (Nintedanib).

This trial will compare progression-free survival and surgical complications of 188 patients with FIGO stage IIIC/IV treated in first line with either neo-adjuvant chemotherapy (carboplatin & paclitaxel) and interval debulking surgery or the same treatment + Vargatef® (Nintedanib).

France: Search for Predictors of Therapeutic Response in Ovarian Carcinoma - Full Text View - ClinicalTrials.gov

Search for Predictors of Therapeutic Response in Ovarian Carcinoma (miRSa)

This study is currently recruiting participants.

Verified February 2012 by Centre Francois Baclesse

First Received on July 8, 2011. Last Updated on February 23, 2012 History of Changes

Further study details as provided by Centre Francois Baclesse:

Primary Outcome Measures:

• search for predictors of response to chemotherapy [ Time Frame: 12 months after beginning treatment ] [ Designated as safety issue: No ]
  the search for predictors of response to chemotherapy in patients with carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced by using (i) the miRNA profile of serum before treatment with chemotherapy and (ii) the identification of polymorphisms or SNPs (Single Nucleotide polymorphism) in particular genes involved in the metabolism of chemotherapy agents
  
  

Secondary Outcome Measures:

• profiling miRNA expression [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  - Characterization of the response to treatment with profiling miRNA expression after the first course of chemotherapy in patients with carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced
  
  
• study of changes in serum miRNA expression [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  - The study of changes in serum miRNA expression identified as predictive of tumor response during chemotherapy treatment.

 

Multinational Comparisons of Health Systems Data, 2011 - The Commonwealth Fund including link to 2011 patient care coordination (11 countries)

"International comparisons of health care systems offer valuable tools to health ministers, policymakers, and academics wishing to evaluate the performance of their country's system. In this chartbook, we use data collected by the Organization for Economic Cooperation and Development (OECD) to compare health care systems and performance on a range of topics, including spending, hospitals, physicians, pharmaceuticals, prevention, mortality, quality of care, and prices. We present data across several industrialized countries: Australia, Canada, Denmark, France, Germany, Japan, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States. Whenever possible, we also present the median value of all 34 members of the OECD.......

Downloads

• Chartbook (248K PDF)
• • Chartbook (626K PPT) 

    Related

    • In the Literature
      • New 2011 Survey of Patients with Complex Care Needs in Eleven Countries Finds That Care Is Often Poorly Coordinated

About INCTR - INCTR – International Network for Cancer Treatment and Research

INCTR is located in Brussels.
It currently has branches in Brazil, Canada, Egypt, France, Nepal and the USA and offices in Cameroon, India, Tanzania and the UK.

Reports:

• A Decade of INCTR: Challenges and Opportunities
• Panel Discussion: Towards A Global Cancer control Program
• Report on Evolution of Pathology Program
• Oncology Nursing Program
• Psychosocial Program
• Development of an INCTR Faculty and Partnerships with Universities
• Open Educational Resources for Cancer (OERC): Two Years of Progress
• Report on Telepathology Meeting, Ile-Ife, Nigeria

2010 newsletter:

"In 2010, cancer overtook ischaemic heart disease as the leading cause of death in the world. While different groupings of diseases (e.g., combining all cardiovascular disease or dividing cancer into many different types) would produce a different rank order, the point should not be missed that cancer can no longer be ignored by global health policy-makers as a major cause of disability or death, as well as economic loss......."

Abstract/full free access: Population-based study of ovarian cancer in Cote d'Or (France): prognostic factors and trends in relative survival rates over the last 20 years

Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers-France

Note: ignore the small spelling errors in the article as it was translated from French to English